Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | MicrobiomeTrials← Back to trialsNCT05552755
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-07-10Est. Completion: 2027-06
Enrollment target: 67 participants Locations- Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
- Del Sol Research Management, Tucson, Arizona, United States
- Medical Associates Research Group, San Diego, California, United States
- GI Pros, Naples, Florida, United States
- Digestive and Liver Center of Florida, Orlando, Florida, United States
- Gastroenterology Health Partners, PLLC, New Albany, Indiana, United States
- Tandem Clinical Research, Marrero, Louisiana, United States
- Corewell Health (Spectrum Health Hospitals Colorectal Cancer Multis), Grand Rapids, Michigan, United States
- Mayo Clinic - Rochester, Rochester, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Gastro One-8110 Walnut Rs, Cordova, Tennessee, United States
- Vanderbilt Digestive Center, Nashville, Tennessee, United States
- Genetic Cancer Prevention Clinic - UT Southwestern, Dallas, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Familial Adenomatous Polyposis
This study reviews post study clinical endoscopy reports in follow up to patients who participated in MAY2016-07-01 with…
Rochester, United StatesCompleted Oct 28, 2021
Familial Adenomatous Polyposis (FAP)
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in pati…
Arcadia, United StatesEst. completion Jul 2030
Huntsman Cancer Institute and University of Utah, Salt Lake City, Utah, United StatesBenaroya Research Institute at Virginia Mason, Seattle, Washington, United States